{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:47:26Z","timestamp":1772754446043,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10067-015-2962-6","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T04:15:04Z","timestamp":1430712904000},"page":"1039-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tumor necrosis factor-\u03b1 antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study"],"prefix":"10.1007","volume":"34","author":[{"given":"Ko-Ming","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien-Tsai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"issue":"9285","key":"2962_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903\u2013911","journal-title":"Lancet"},{"issue":"11","key":"2962_CR2","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118(11):3537\u20133545","journal-title":"J Clin Invest"},{"issue":"7","key":"2962_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N","volume":"43","author":"MJ Plant","year":"2000","unstructured":"Plant MJ, Williams AL, O\u2019Sullivan MM, Lewis PA, Coles EC, Jessop JD (2000) Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 43(7):1473\u20131477","journal-title":"Arthritis Rheum"},{"issue":"29","key":"2962_CR4","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.2174\/138161211798157658","volume":"17","author":"J Geiler","year":"2011","unstructured":"Geiler J, Buch M, McDermott MF (2011) Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des 17(29):3141\u20133154","journal-title":"Curr Pharm Des"},{"issue":"6","key":"2962_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762\u2013784","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2962_CR6","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1128\/JVI.76.11.5646-5653.2002","volume":"76","author":"V Pasquetto","year":"2002","unstructured":"Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV (2002) Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76(11):5646\u20135653","journal-title":"J Virol"},{"issue":"3","key":"2962_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1084\/jem.179.3.841","volume":"179","author":"R Gonzalez-Amaro","year":"1994","unstructured":"Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L et al (1994) Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 179(3):841\u2013848","journal-title":"J Exp Med"},{"issue":"1","key":"2962_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26\u201337","journal-title":"Arthritis Rheum"},{"issue":"9410","key":"2962_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675\u2013681","journal-title":"Lancet"},{"issue":"22","key":"2962_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343(22):1594\u20131602","journal-title":"N Engl J Med"},{"issue":"9194","key":"2962_CR11","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932\u20131939","journal-title":"Lancet"},{"issue":"1","key":"2962_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2000","unstructured":"Weinblatt ME, Keystone EC, Furst DE et al (2000) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35\u201345","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2962_CR13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/039463200902200233","volume":"22","author":"C Giannitti","year":"2009","unstructured":"Giannitti C, Benucci M, Caporali R et al (2009) Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 22(2):543\u2013546","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"2962_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2962_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","volume":"11","author":"C Benichou","year":"1990","unstructured":"Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11(2):272\u2013276","journal-title":"J Hepatol"},{"issue":"20","key":"2962_CR16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMc060733","volume":"354","author":"N Mumoli","year":"2006","unstructured":"Mumoli N, Cei M, Cosimi A (2006) Drug-related hepatotoxicity. N Engl J Med 354(20):2191\u20132193, author reply \u22123","journal-title":"N Engl J Med"},{"issue":"3","key":"2962_CR17","first-page":"421","volume":"35","author":"DU Cansu","year":"2008","unstructured":"Cansu DU, Kalifoglu T, Korkmaz C (2008) Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 35(3):421\u2013424","journal-title":"J Rheumatol"},{"issue":"2","key":"2962_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.autrev.2008.05.002","volume":"8","author":"I Cavazzana","year":"2008","unstructured":"Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F (2008) Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 8(2):104\u2013106","journal-title":"Autoimmun Rev"},{"issue":"10","key":"2962_CR19","first-page":"1944","volume":"35","author":"C Ferri","year":"2008","unstructured":"Ferri C, Ferraccioli G, Ferrari D et al (2008) Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 35(10):1944\u20131949","journal-title":"J Rheumatol"},{"issue":"7","key":"2962_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10067-009-1149-4","volume":"28","author":"S Li","year":"2009","unstructured":"Li S, Kaur PP, Chan V, Berney S (2009) Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 28(7):787\u2013791","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2962_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/art.20702","volume":"51","author":"FA Parke","year":"2004","unstructured":"Parke FA, Reveille JD (2004) Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51(5):800\u2013804","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2962_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","volume":"62","author":"JR Peterson","year":"2003","unstructured":"Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62(11):1078\u20131082","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2962_CR23","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","volume":"45","author":"CH Roux","year":"2006","unstructured":"Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45(10):1294\u20131297","journal-title":"Rheumatology"},{"issue":"4","key":"2962_CR24","first-page":"290","volume":"17","author":"C Vauloup","year":"2006","unstructured":"Vauloup C, Krzysiek R, Greangeot-Keros L et al (2006) Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 17(4):290\u2013293","journal-title":"Eur Cytokine Netw"},{"issue":"9","key":"2962_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","volume":"50","author":"AM Brunasso","year":"2011","unstructured":"Brunasso AM, Puntoni M, Gulia A, Massone C (2011) Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology 50(9):1700\u20131711","journal-title":"Rheumatology"},{"issue":"9","key":"2962_CR26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD et al (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69(9):1612\u20131617","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2962_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Du Pan","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61(5):560\u2013568","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2962_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from 8\u00a0years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62(1):22\u201332","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2962_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1056\/NEJM199107113250205","volume":"325","author":"P Farci","year":"1991","unstructured":"Farci P, Alter HJ, Wong D et al (1991) A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 325(2):98\u2013104","journal-title":"N Engl J Med"},{"issue":"6","key":"2962_CR30","first-page":"979","volume":"23","author":"MR Lovy","year":"1996","unstructured":"Lovy MR, Starkebaum G, Uberoi S (1996) Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 23(6):979\u2013983","journal-title":"J Rheumatol"},{"issue":"3","key":"2962_CR31","first-page":"613","volume":"21","author":"BD Clifford","year":"1995","unstructured":"Clifford BD, Donahue D, Smith L et al (1995) High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21(3):613\u2013619","journal-title":"Hepatology"},{"issue":"9","key":"2962_CR32","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","volume":"44","author":"S Cohen","year":"2001","unstructured":"Cohen S, Cannon GW, Schiff M et al (2001) Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with Methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial investigator group. Arthritis Rheum 44(9):1984\u20131992","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2962_CR33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68(7):1100\u20131104","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2962-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-015-2962-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2962-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-2962-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:48:07Z","timestamp":1744174087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-015-2962-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["2962"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-2962-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]},"assertion":[{"value":"8 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}